Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BPL-5MeO
- Development stage
- Discontinued
- Lead developer
- Beckley Psytech
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
BPL-5MeO is a liquid nasal spray formulation of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), a potent psychedelic tryptamine. Developed by Beckley Psytech, it was primarily investigated for the treatment of treatment-resistant depression (TRD). The drug acts as an agonist at serotonin receptors, with high affinity for the 5-HT1A and 5-HT2A subtypes, which are thought to mediate its rapid-acting antidepressant effects and psychedelic experiences. In a Phase 1 first-in-human study (BPL-5MeO-101), the liquid formulation demonstrated a favorable safety profile and dose-proportional pharmacokinetics in healthy volunteers. However, Beckley Psytech has since discontinued development of the liquid spray in favor of BPL-003, a dry powder nasal spray formulation of 5-MeO-DMT, which is currently in Phase 2 clinical trials.
- Other names
- 5-methoxy-N,N-dimethyltryptamine
02
Targets
HTR2A (Serotonin receptor 5-HT2A)ADRA1A (α1A)HTR2C (5-hydroxytryptamine 2C receptor)HTR2B (5-Hydroxytryptamine Receptor 2B)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on BPL-5MeO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BPL-5MeO.